The advanced glycation end products market comprise products used to inhibit the formation of advanced glycation end products in the human body. Advanced glycation end products or AGEs are compounds formed in the body as a result of a reaction between sugars and amino acids. The accumulation of AGEs in tissues and blood has been associated with aging and various chronic diseases including diabetes, renal failure, and cardiovascular diseases. There has been a rising prevalence of chronic and lifestyle-related diseases globally, fueling the demand for AGE inhibitor therapies.

The global advanced glycation end products market is estimated to be valued at US$ 3,469.95 Mn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030.

Key Takeaways

Key players operating in the advanced glycation end products market are Lonza Group, DSM, Thermo Fisher Scientific Inc., Mediwest Pharmaceuticals Co. Ltd., and Immunoclin Corp.

The market is expected to witness significant growth opportunities due to the growing research on application of AGE inhibitors in neurodegenerative diseases and cancer treatment.There is an increasing focus on developing AGE inhibitor drugs for oral administration to improve patient compliance.

Globally, there is rising investment for research on AGE breakers and cross-link breakers and their mechanisms of action. Additionally, expansion of healthcare infrastructure and medical reimbursement programs in developing regions will boost the global demand for AGE inhibitor therapies.

Market drivers

The rising prevalence of diabetes and associated chronic conditions is a key driver propelling the advanced glycation end products market growth. According to the International Diabetes Federation, around 537 million adults were living with diabetes in 2021 worldwide and the number is projected to rise to 643 million by 2030 and 783 million by 2045. Advanced glycation end products play an important role in diabetes complications. Hence, increased focus on management of diabetes-related comorbidities will drive the demand for AGE inhibitor drugs over the forecast period.

PEST Analysis

Political: Regulations on the production, distribution and marketing of drugs can impact the advanced glycation end products market. Stringent approval processes for new drugs can slow market growth.

Economic: The rising healthcare expenditure across countries and growing aging population are increasing the demand for advanced therapies to treat chronic diseases associated with aging. This favors market expansion.

Social: Shift in lifestyle behavior leading to growing incidence of chronic diseases like diabetes and cardiovascular disorders drives the need for therapies targeting advanced glycation end products.

Technological: Continuous research aims to develop more effective drugs with lesser side effects. Emerging methods to convert nanoemulsions into gels can facilitate controlled and targeted drug delivery.

The geographical regions where the advanced glycation end products market is concentrated in terms of value are North America and Europe. The high healthcare expenditure, growing aging population, and presence of major players in these regions contribute to their large market share.

Asia Pacific is anticipated to be the fastest growing region for the advanced glycation end products market during the forecast period. Factors such as rising incidence of chronic diseases, increasing healthcare expenditure, growing geriatric population, and enhancing research initiatives are expected to drive the market in Asia Pacific.